Novasep Attracts Top Talent to Complete its Executive Team
News Jan 20, 2014
Novasep has announced that it has appointed Thierry van Nieuwenhove as president of the Synthesis Business Unit. Van Nieuwenhove’s arrival completes Novasep’s executive committee.
With its full executive committee (COMEX) now on board, Novasep achieves another key milestone in its strategic development.
Educated as a bio-engineer, Van Nieuwenhove, 40, holds a masters degree in chemistry and biochemistry from the Catholic University of Louvain, Belgium.
He joins Novasep from Ajinomoto-Omnichem, a European synthetic molecules custom manufacturing organization (CMO) owned by a top Japanese firm, where he held consecutive positions as director, then general manager and member of the board.
His skill set includes driving business unit growth, leading global teams including sales and business development, R&D, supply chain and purchasing, as well as mergers and acquisitions.
“We are thrilled to welcome Thierry to Novasep as president of the Synthesis Business Unit,” said Michel Spagnol, CEO of Novasep. “His broad experience in driving multicultural custom synthesis businesses will complement our COMEX skills perfectly. Thierry possesses the dynamics to boost Novasep’s CMO business in all our key markets.”
“I am very pleased to join Novasep,” said Thierry Van Nieuwenhove. “With its unique pool of specialized technologies and talents, Novasep is well positioned for growth as a top tier service provider for the life sciences industry. The group as a whole has tremendous opportunities to develop. Really innovative solutions can come out from the cross-fertilization of its several specialized technologies and application markets that will build future Novasep expertise. I am excited to be part of it.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018